Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

AstraZeneca has presented results for the SERENA-6 trial at the American Society for Medical Oncology (ASMO)'s 2025 ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of ...

The latest trading session saw Astrazeneca (AZN) ending at $71.93, denoting a -1.24% adjustment from its last day's close.

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...

AstraZeneca (AZ) has announced that a wider range of chronic kidney disease (CKD) patients across England and Wales will be ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

M42 will integrate SOPHiA GENETICS’ MSK-ACCESS® powered with SOPHiA DDM™ technology into its testing infrastructure ...

AstraZeneca Pharma India rallied nearly 12 per cent after its net profit for the fourth quarter of the previous financial ...